Slide 1: 4Q & FY 2023 Results Conference Call and Webcast
4Q & FY 2023 Results Conference Call and Webcast March 6, 2024 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Q4 Earnings Results Call Agenda
Q4 Earnings Results Call Agenda Chris Astle, PhD Paul Moore, PhD Ken Galbraith SVP & CFO CSO Chair and CEO • Financial Update • R&D Update • Q&A • Q&A • Q&A Making a Meaningful Difference 3
Slide 4: Chris Astle, PhD
Chris Astle, PhD Senior Vice President & Chief Financial Officer Making a Meaningful Difference 4
Slide 5: 2023 in Review: Selected Key Milestones
2023 in Review: Selected Key Milestones • Positive results from Phase 2 study in 1L • ZW220 announced as preclinical • On track for anticipated IND GEA for zanidatamab (zani) at ASCO GI product candidate for an IND submissions for ZW171 and ZW191 submission in 2025 • Multiple data catalysts highligh
Slide 6: Zanidatamab: $2B+ Peak Sales Potential
Zanidatamab: $2B+ Peak Sales Potential* Expect to enter market first in BTC (pending regulatory approval)1 Represents ~12,000 HER2+ cases annually2 1 • Rolling BLA submission for accelerated approval in 2L BTC In USA, Europe3, and • Confirmatory Phase 3 trial initiated in 1L metastatic BTC Japan Pat
Slide 7: 5x5 R&D Strategy: Diversified Portfolio Beyond Zanidatamab
5x5 R&D Strategy: Diversified Portfolio Beyond Zanidatamab with Multiple Opportunities for Success ZW191 (FR⍺) ZW171 (MSLN) Antibody-Drug Conjugate Bispecific T-Cell Engager (2+1) targeting folate receptor alpha targeting ovarian, NSCLC, and other expressing tumors including mesothelin-expressing ca
Slide 8: Full Year 2023 Financial Results
Full Year 2023 Financial Results • Revenue decrease in 2023 primarily driven by primarily due to a non-recurring upfront fee of $375.0M from Jazz in 2022. This was partially offset by higher development support and In millions USD Full Year 2023 Full Year 2022 drug supply revenue from Jazz in 2023 d
Slide 9: Projected Cash Runway Supports R&D Priorities into 2H 2027
Projected Cash Runway Supports R&D Priorities into 2H 2027 Potential sources to extend cash runway Current Financial Status: beyond 2H 2027: • Cash resources1 of approx. $456.3M • Additional regulatory approval and (as of December 31, 2023) commercial milestones for zanidatamab from Jazz and BeiGene
Slide 10: Paul Moore, PhD
Paul Moore, PhD Chief Scientific Officer Making a Meaningful Difference 10
Slide 11: Novel Camptothecin Payload Selected with ADCs in Mind
Zymeworks Novel Camptothecin Payload was Selected with ADCs in Mind A-1743332 Exatecan YL0010014 AMDCPT 9106-IM-2 Ed-04 KL610023 Potency SN-38 AZ’0133 ZD06519 DXd Known experimental drugs Novel payloads repurposed as ADC payloads developed for ADCs Design of novel payloads enables incorporation of p
Slide 12: Robust Interrogation Yields Pipeline Ready TOPO1i ADC Platform
Robust Interrogation Yields Pipeline Ready TOPO1i ADC Platform From concept to platform: Payload Conjugation ADC In vitro In vivo Rodent Non-human Lead synthesis & of select biophysical potency & anti-tumor activity tolerability primate selection screening payloads characterization stability & PK to
Slide 13: Majority of ADCs Showed Optimal Potency and Bystander Activity
Majority of ADCs Showed Optimal Potency and Bystander Activity Target-dependent activity Bystander active payloads nM: nanomolar Making a Meaningful Difference 13
Slide 14: ZD06519 Payload is Being Utilized in Multiple Pipeline Programs
ZD06519 Payload is Being Utilized in Multiple Pipeline Programs ZW191 ZW220 ZW251 Target FRα NaPi2b GPC3 Format/Technology Monospecific/TOPO1i ADC Monospecific/TOPO1i ADC Monospecific/TOPO1i ADC Ovarian cancer, other gynecological Potential Indications Ovarian cancer, NSCLC Hepatocellular carcinoma
Slide 15: Extensive Expected News Flow over 2024 and 2025
Extensive Expected News Flow over 2024 and 2025 1H 2024 2H 2024 2025 PIPELINE EVENTS • Expect to complete USA regulatory • Pivotal Phase 3 top-line data readout in • Potential USA and China launch for submission for zanidatamab in 2L BTC GEA 1L targeted in late 2024 zanidatamab in 2L BTC and initial
Slide 16: A Differentiated Product Pipeline Built on Unique Capabilities
Zymeworks: A Differentiated Product Pipeline Built on Unique Capabilities in Antibody Engineering and Medicinal Chemistry Seeking to address unmet patient 5 new INDs planned Continuing to innovate and move needs in HER2+ GI Cancers Focus on Gyn CA, Lung CA, & GI CA beyond oncology zanidatamab • ZW17
Slide 17: Milestone Opportunities in 2024 & 2025
Milestone Opportunities in 2024 & 2025 Several opportunities for business Cash resources as of development with global rights for December 31, 2023 $456.3M* novel compounds Current cash runway projected to Multiple value generating support development goals into the opportunities expected in 2024 an
Slide 18: Q&A
Q&A Ken Galbraith Chair and CEO Chris Astle, PhD SVP and CFO Paul Moore, PhD CSO Making a Meaningful Difference